For depression in dementia, sertraline, citalopram and escitalopram show little extra benefit over placebo after weeks of use, so safety drives the choice. SSRIs, selective serotonin reuptake inhibitors, are drugs that raise serotonin activity to ease low mood. A 2018 Cochrane review found little or no difference in depression scores after 6-13 weeks between these drugs and placebo. This comparison weighs mood benefit against agitation effects, thinking decline, and heart rhythm risk.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Do they ease depression in dementia?
- What about agitation?
- Which safety risks differ most?
- How should treatment start and be checked?
Do they ease depression in dementia?
The Cochrane evidence covers double-blind trials in people with dementia. It found little or no separation from placebo for sertraline, citalopram and escitalopram.
The UK HTA-SADD trial tested the question longer in 326 Alzheimer patients. Sertraline showed no better depression scores than placebo at 13 and 39 weeks, with more adverse events on active drugs.
What about agitation?
Agitation means restlessness, aggression, or distress that harms daily care. It responds differently than low mood. In the CitAD trial of 186 patients, citalopram 30 mg per day plus psychosocial care improved agitation markedly in about 40% versus 26% on placebo.
The same trial showed QT prolongation and worse cognition on citalopram. QT means the heart's electrical recovery time between beats. In the 12-week S-CitAD phase 3 trial of 173 patients, escitalopram up to 15 mg per day did not significantly improve Alzheimer agitation versus placebo, about 35% versus 27%. It also caused cardiac conduction delays, which are slowed electrical signals in the heart.
Which safety risks differ most?
A Swedish national cohort analysis of 18,740 dementia patients linked antidepressant use to 0.30 extra MMSE points lost per year. MMSE is a 30-point test of memory and thinking. Decline was fastest with escitalopram at 0.76 points, then citalopram at 0.41, then sertraline at 0.25.
The cohort design cannot prove the drugs caused the faster decline. The UBC Therapeutics Initiative found no adequate trial evidence that escitalopram carries lower QT-related risk than citalopram. It concluded escitalopram's dominance reflects marketing rather than comparative efficacy or safety evidence.
How should treatment start and be checked?
UBC dose guidance notes citalopram prolongs QT with higher doses. The FDA label caps citalopram at 20 mg per day over age 60, in liver impairment, in CYP2C19 poor metabolizers, or with CYP2C19 inhibitors. CYP2C19 is a liver enzyme that breaks down these drugs.
Escitalopram is usually capped at 20 mg, with 10 mg recommended in older adults. S-CitAD was smaller than planned, which limits certainty about escitalopram for agitation. Clinicians generally reserve SSRIs for moderate to severe dementia depression and start low. Practical checks include:.
- confirm depression severity and review other causes of low mood
- start at a low dose and watch for falls, nausea, agitation, or confusion
- get baseline and follow-up ECGs for citalopram or escitalopram. ECG is a heart-rhythm tracing.
